Glenmark Pharmaceuticals Ltd (GLENMARK) — Announcement | 11 September 2026(2 announcements)
Glenmark Pharmaceuticals announced the launch of RYALTRIS Nasal Spray in Brazil for allergic rhinitis, marking its first globally commercialized branded innovative product in Latin America and expanding its respiratory innovation footprint.
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to IND AA+ from IND AA with a Stable Outlook, while affirming short-term loans at IND A1+. The upgrade follows a USD560 million upfront payment from AbbVie under an ISB 2001 licensing deal, which significantly de-risks innovation spending and strengthens the balance sheet. The company now holds zero gross debt and improved liquidity, with cash balances of INR11.8 billion at FYE26. The rationale highlights enhanced financial visibility, diversified business profile, and strong US revenue recovery driven by the licensing transaction, though regulatory risks in India and the US persist.
About Glenmark Pharmaceuticals Ltd (GLENMARK)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when GLENMARK files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track GLENMARK — Free💡 Ask AI about this filing
📊 More GLENMARK filings
- Announcement — 20 August 2026 Glenmark Pharmaceuticals announced U.S. FDA approval for its generic Fluticasone Propionate Nasal Sp...
- 🟡 Board Meeting — 13 August 2026 Glenmark Pharmaceuticals announced its 48th AGM on September 11, 2026, via video conferencing, where...
- 🔴 Annual Report — 13 August 2026 Glenmark Pharmaceuticals disclosed on August 13, 2026 that shareholders without registered email add...
- Announcement — 11 August 2026 Glenmark Pharmaceuticals disclosed a settlement agreement with Humana to resolve U.S. antitrust liti...
- 🔴 Corporate Action — 10 August 2026 Glenmark Pharmaceuticals allotted 23,863 equity shares of Re. 1 each on August 10, 2026, under its E...
🔥 Also filed on 11 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GLENMARK files new disclosures
Track GLENMARK filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GLENMARK — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd